Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
exenatide + dapagliflozin
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Peptides, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
Exenatide + dapagliflozin is a fixed-dose combination therapy for type 2 diabetes mellitus. Exenatide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) that enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion, and slows gastric emptying. Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, leading to increased urinary glucose excretion. The combination provides additive benefits in glycemic control, weight reduction, and systolic blood pressure lowering compared to either agent alone in patients with type 2 diabetes inadequately controlled on metformin[1][4][6]. Both drugs are administered separately but have been studied together in clinical trials for their complementary mechanisms of action.
- Brand names
- BydureonFarxigaForxiga
- Other names
- exenatide + dapagliflozin
02
Targets
SGLT2 (Sodium-glucose cotransporter protein subunit 2)GLP1R (GLP-1R)
Beyond the preview
Go deeper on exenatide + dapagliflozin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on exenatide + dapagliflozin.